Marksans Pharma Ltd - Pharmaceutical Company India
Follow Us On :
  • About Us
    • Company Profile
    • From the Chairman's Desk
    • Vision, Core Values
    • Milestones
    • Board of Directors
    • Management Profile
    • Mergers & Acquisitions
    • International Operations
    • Strategy
    • Subsidiaries
    • R & D Capabilities
    • Quality Policy
    • Corporate Social Responsibility
    • World Wide Operations
  • Formulation Business
    • Overview
    • Markets
      •  
      • USA
      • Europe
      • South East Asia
      • Africa
      • Russia & CIS
      • Latin America
      • Australasia
      •  
    • Manufacturing Facilities
      •  
      • Locations (Goa/ Southport - UK)
      •  
  • R & D
    • CRAMS
    • Out Licensing
    • Business Development
  • Investor Relations
    • Financial Results
      •  
      • Annual Reports
      • Quarterly Reports
      • Analysts Presentation
      •  
    • Compliances
    • Shareholding Pattern
    • PD
    • Contact Us
  • News
    • Press Release
    • Media Gallery
  • Industry Overview
  • Health and Illness
    • Oncology And Critical Care
    • The Disorders Of The Mind And Nerves
      •  
      • Neurological Disorder
      • Mental Disorders
      •  
    • Skin Infections And Ulcers
    • Gastro - Intestinal Disorders (GI)
    • Cough Remedies
    • Women's Health
    • Bacterial Infections And Its Treatment
  • Blog
  • Careers
    • Overview
    • Values
    • Life at Marksans
  • Contact Us
  • Home
  • About Us
    • Company Profile
    • From the Chairman's Desk
    • Vision, Core Values
    • Milestones
    • Board of Directors
    • Management Profile
    • Mergers & Acquisitions
    • International Operations
    • Strategy
    • Subsidiaries
    • R & D Capabilities
    • Quality Policy
    • Corporate Social Responsibility
    • World Wide Operations
  • Formulation Business
    • Overview
    • Markets
      • USA
      • Europe
      • South East Asia
      • Africa
      • Russia & CIS
      • Latin America
    • Manufacturing Facilities
      • Locations (Goa/ Southport - UK)
  • R & D
    • CRAMS
    • Out Licensing
    • Business Development
  • Investor Relations
    • Financial Results
      • Annual Reports
      • Quarterly Reports
      • Analysts Presentation
    • Compliances
    • Shareholding Pattern
    • PD
    • Contact Us
  • News
    • Press Release
    • Media Gallery
  • Industry Overview
  • Health and Illness
    • Oncology And Critical Care
    • The Disorders Of The Mind And Nerves
      • Neurological Disorder
      • Mental Disorders
    • Skin Infections And Ulcers
    • Gastro - Intestinal Disorders (GI)
    • Cough Remedies
    • Women's Health
    • Bacterial Infections And Its Treatment
  • Blog
  • Careers
    • Overview
    • Values
    • Life at Marksans
  • Contact Us
  • Site Map

News

  • Press Release
  • Media Gallery
Corporate Social Responsibility by Marksans Pharma Ltd

Home News

Press Release

  • Performance Highlight - Consolidated Q3 2018-19
  • Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine
    5mg / 5ml Oral Solution
  • Performance Highlight – Consolidated for H1 2018-19
  • Performance Highlight – Consolidated Q1 2018-19
  • Transfer of Shares in dematerialised form only
  • Performance Highlight – Consolidated Q4 2017-18
  • Performance Highlight – Consolidated Q3 2017-18
  • Performance Highlight - Consolidated for H1 2017-18
  • Performance Highlight - Consolidated Q1 2017-18
  • Receipt of Establishment Inspection Report
  • Performance Highlights - Consolidated
  • Marksans Pharma Limited - US FDA
  • Marksans Pharma Limited Announcement
  • Performance Highlights - Consolidated
  • Performance Highlights - Consolidated
  • Performance Highlights - Consolidated
  • Performance Highlights - Consolidated
  • Marksans Pharma Limited announces USFDA approval for Metformin Hydrochloride Extended Release
  • News Release March 2016
  • News Release February 2016
  • News Release January 2016
  • News Release November 2015
  • News Release August 2015
  • News Release June 2015
  • News Release May 2015
  • News Release February 2015
  • News Release September 2014
  • Proceedings of 22nd AGM
  • Report of the Scrutinizer
  • Addendum to Notice of 22nd Annual General Meeting
  • News Release June 14
  • Home
  • About Us
    • Company Profile
    • From the Chairman's Desk
    • Vision, Core Values
    • Milestones
    • Board of Directors
    • Management Profile
    • Mergers & Acquisitions
  • News
    • Press Release
    • Media Gallery
  •  
  •  
    • International Operations
    • Strategy
    • Subsidiaries
    • R & D Capabilities
    • Quality Policy
    • Corporate Social Responsibility
    • World Wide Operations
  • Industry Overview
  • Formulation Business
    • Overview
    • Markets
    • Manufacturing Facilities
  • Health and Illness
    • Oncology And Critical Care
    • The Disorders Of The Mind And Nerves
    • Skin Infections And Ulcers
    • Gastro - Intestinal Disorders (GI)
    • Cough Remedies
    • Women's Health
    • Bacterial Infections And Its Treatment
  • R & D
    • CRAMS
    • Out Licensing
    • Business Development
  • Investor Relations
    • Financial Results
    • Compliances
    • Shareholding Pattern
    • PD
    • Contact Us
  • Blog
  • Careers
    • Overview
    • Values
    • Life at Marksans
  • Site Map
  • Contact Us
© Copyright 2013 Marksans Pharma.